Microbial Cell Factories: A Review of Mainstream Yeast Chassis for Synthetic Biology Industrial Production

Most people associate yeast solely with bread baking and wine fermentation. In synthetic biology, however, yeast has transcended traditional food fermentation applications to become editable, programmable microscopic cell factories. Using gene knockout and metabolic pathway reconstruction, researchers engineer these single-celled microbes to consume glucose, methanol, and straw hydrolysates, biosynthesizing pharmaceutical proteins, cosmetic active ingredients, natural flavors, feed proteins and bulk biochemicals.

Compared with prokaryotic chassis such as E. coli, yeast as eukaryotic microorganisms possesses intrinsic capacities for protein folding, glycosylation and secretory expression, making them preferred platforms for manufacturing recombinant proteins and complex natural products.

With the widespread adoption of CRISPR gene editing, metabolic network modelling and AI-assisted strain engineering, Saccharomyces cerevisiae is no longer the only dominant yeast chassis. Non-conventional yeasts including Komagataella phaffii, Yarrowia lipolytica, Kluyveromyces marxianus and Pichia kudriavzevii have moved beyond laboratory research and demonstrated strong performance in industrial biomanufacturing. These yeasts differ greatly in tolerance profiles, preferred carbon sources and target product spectra. Selecting the right yeast chassis is the first critical step to successful fermentation scale-up and production cost reduction. This article reviews leading industrial yeast cell factories, analysing their strengths, suitable applications and commercial bottlenecks to clarify core principles for synthetic biology chassis selection.

1. Classic Model Chassis: Saccharomyces cerevisiae

Saccharomyces cerevisiae is the most thoroughly studied yeast with well-characterized genetic background, serving as the benchmark cell factory for synthetic biology. It features mature genetic tools, simple cultivation protocols and GRAS status, gaining broad acceptance across food and pharmaceutical industries.

It excels at de novo biosynthesis of terpenoids, polyphenols and plant-derived natural products. The famous synthesis of artemisinic acid (the precursor of artemisinin) was achieved using S. cerevisiae, reshaping the industry landscape previously relying on plant extraction. Its product portfolio covers nutritional additives, pharmaceutical intermediates and natural flavors. Many triterpenes and sesquiterpenes such as corosolic acid, maslinic acid, farnesene and squalene are commonly synthesized in this chassis. It can also produce recombinant proteins; early hepatitis B vaccine strains adopted S. cerevisiae expression systems.

Nevertheless, it has notable limitations. Its native metabolism favours ethanol formation. Carbon flux easily diverts toward ethanol under high glucose conditions due to the Crabtree effect, restricting high-cell-density fermentation. Secretory recombinant protein titres are generally lower than those from Komagataella phaffii, and its capability for fatty acid and lipid synthesis lags behind Yarrowia lipolytica. Industrially, S. cerevisiae is now mainly deployed for high-value, low-volume natural product development. Bulk chemicals and large-scale recombinant protein projects increasingly turn to non-conventional yeast alternatives.

2. Leader in Recombinant Protein Production: Komagataella phaffii (formerly Pichia pastoris)

If S. cerevisiae is a laboratory favourite, Komagataella phaffii is the workhorse chassis widely adopted in industrial bioreactors for cosmetic raw materials and recombinant protein manufacturing. It is the preferred host for many recombinant antifungal proteins and therapeutic active proteins.

Its signature advantage lies in the strong methanol-inducible AOX1 promoter, supporting high-density fermentation and high OD biomass. Exogenous proteins are predominantly secreted into fermentation supernatant, greatly simplifying downstream purification. As a eukaryotic host, it enables proper protein folding, disulfide bond formation and glycosylation, ideal for enzyme preparations, cosmetic recombinant proteins, peptides and therapeutic proteins. Many domestic projects for hyaluronic acid-related enzymes, recombinant collagen, industrial enzymes and feed protein rely on this Pichia expression platform.

Recent advances in strain engineering have generated methanol-tolerant Komagataella phaffii strains, which use methanol as the sole carbon source to synthesize high-value molecules. High-titer fermentation of β-arbutin, p-coumaric acid and dopamine has been realized. Commercial demonstration lines for methanol-to-feed-protein at ten-thousand-ton scale have opened new non-food biomanufacturing routes.

The main bottleneck is glycosylation: native Komagataella phaffii produces high-mannose glycans different from human-type glycosylation. Humanized glycan engineering is required if it is used for injectable therapeutic proteins. Traditional methanol induction also brings safety risks due to flammability and relatively long induction cycles. Constitutive promoter engineering and methanol tolerance improvement are active research directions. Overall, Komagataella phaffii remains the most cost-effective, well-validated yeast chassis for secretory recombinant protein fermentation.

3. Lipid-Specialized Chassis: Yarrowia lipolytica

Yarrowia lipolytica is an oleaginous yeast with natural lipid accumulation capacity and abundant intracellular acetyl-CoA pools. It is a perfect chassis for fatty acids, bio-lipids, wax esters and lipophilic terpenoids. Unlike other yeasts, it can utilize oils, glycerol and hydrophobic substrates, and tolerates product toxicity caused by lipophilic metabolites.

Industrially, it is used to produce bio-oils, triacontane, citrate and triacetin. It is a leading candidate for long-chain dicarboxylic acids and biodegradable polymer monomers, with promising applications in flavours and lipid-soluble nutraceutical raw materials.

Its drawbacks include less mature genetic toolkits compared with S. cerevisiae and Komagataella phaffii. Secretory protein expression is weak, making it unsuitable for large-scale production of water-soluble recombinant proteins. Strain engineering barriers are higher, and industrial cases remain limited, mostly confined to lipid biomanufacturing.

4. High-Temperature Resilient Chassis: Kluyveromyces marxianus

Most industrial yeasts ferment optimally at 28–30°C, requiring continuous cooling by chillers during large-scale bioreactor operation, which drives up energy consumption. Kluyveromyces marxianus stands out for heat tolerance; it can grow at temperatures close to 50°C.

High-temperature fermentation reduces cooling loads and utility costs, while lowering contamination risks. It accepts a broad range of carbon substrates including xylose, whey and lignocellulosic straw hydrolysates, aligning with circular bioeconomy principles. It is suitable for bulk organic acids, food flavourings and ethyl ester production, and can efficiently consume lactose from dairy by-product whey.

Its limitations: genetic toolboxes are still under development, with limited fine-tuning regulatory elements. Constructing complex multi-step biosynthetic pathways is challenging. Current industrial applications focus on food additives and bulk organic acids; adoption for high-end recombinant proteins is still limited. It represents an emerging chassis with untapped potential.

5. Acid-Tolerant Chassis: Pichia kudriavzevii for Clean Organic Acid Manufacturing

Traditional organic acid fermentation lowers pH continuously as acids accumulate. Base neutralization is required, generating massive salt waste and increasing waste treatment costs. Pichia kudriavzevii can sustain stable growth below pH 3.0. Engineered strains developed by Chinese research teams produce L-lactic acid without alkali addition, eliminating salt waste from the source and enabling greener organic acid bioproduction.

This yeast tolerates high sugar concentrations and environmental stress, suited for high-substrate-density fermentation targeting bioplastic monomers and organic acids. Its weakness is narrow product scope, heavily limited to organic acid biosynthesis. 配套 protein expression technology is far less mature than that of Komagataella phaffii, restricting it to niche applications.

6. Chassis Selection for Industrialization: Suitability Trumps Universal Performance

Many synthetic biology start-ups chase an “all-powerful chassis”. In reality, every yeast has inherent metabolic preferences; no universal cell factory exists.

· Secreted recombinant proteins, industrial enzymes and cosmetic active proteins: Komagataella phaffii is preferred, with abundant scale-up and purification experience.

· Terpenoids, polyphenols, high-value natural products for small-batch high-margin production: Saccharomyces cerevisiae, with the most mature genetic editing toolkit.

· Lipids, long-chain hydrophobic compounds and wax monomers: Yarrowia lipolytica.

· Bulk organic acid production aiming to cut energy consumption and solid waste: Pichia kudriavzevii.

· Low-cost feedstocks such as straw hydrolysate or whey, with energy-saving goals: Kluyveromyces marxianus deserves evaluation.

All yeast cell factories share common industrialization hurdles: metabolic burden from heterologous pathways, product toxicity, scale-up effects from shake flasks to large bioreactors, batch variability, non-uniform glycosylation, target protein degradation and insufficient carbon conversion efficiency. Even promising shake-flask titres often drop drastically after scaling up to hundred-liter or ton-scale fermenters due to changes in dissolved oxygen, shear stress and metabolic homeostasis.

7. Industry Trend: From Single Chassis to Customized Cell Factories

Yeast engineering has evolved beyond simple insertion of one or two foreign genes into systematic, rational cell design. AI-driven pathway prediction, dynamic metabolic switches, biosensors and large-scale genome rearrangement allow separated control: cells prioritize biomass accumulation in growth phase, then redirect carbon flux toward target metabolites in production phase to maximize carbon utilization and reduce metabolic waste.

Gene libraries for non-conventional yeasts keep expanding. Heat-resistant, acid-tolerant and methanol-consuming specialty yeasts are moving from academic labs to ten-thousand-ton demonstration plants. One-carbon biomanufacturing is a major hotspot, using methanol or CO₂ instead of glucose or corn, reducing reliance on food resources and supporting carbon-neutral biomanufacturing policies.

Yeast cell factories will keep reshaping biomanufacturing. These tiny microbial hosts provide a promising alternative to polluting chemical synthesis routes and fossil feedstocks. For fermentation engineers and synthetic biology innovators, matching chassis properties with product specifications, raw material economics, downstream purification and waste requirements is essential to cross the “lab-to-factory” gap. Custom-engineered yeast chassis will continue delivering disruptive green manufacturing solutions for biopharmaceuticals, cosmetic ingredients, advanced materials and agriculture.